News

SOHM said that the pharmaceutical order is expected to drive revenue in 2010 and 2011 as future orders are delivered. SOHM Inc Corporate Strategy vice president Shailesh Shah

The current approval is the second approval of this new oral anticoagulant following the recent marketing authorisation by the US Food and Drug Administration (FDA). The approval is

R-Bambuterol Hydrochloride is categorized as a Class I new drug. In preclinical studies, R-Bambuterol Hydrochloride demonstrated a promising efficacy and safety profile. Obtaining permission from the SFDA Ethics

Novartis plans to expand its current Massachusetts Avenue campus, adjacent to MIT, by more than 400,000 sft, including laboratory, office and retail space. Construction is expected to begin

The three-year project ‘Disease-modifying drug discovery in cystic fibrosis’ focuses on Galapagos’ CF program based on new drug targets, with the goal to deliver a pre-clinical candidate. Galapagos

Eisai obtained the exclusive rights to develop and market KES524 in Japan in an agreement with Abbott. Eisai had submitted a MAA for the agent to the Japanese

HGS has posted a net loss of $40.86m for the third quarter 2010, or $0.22 loss per diluted share, compared to net loss of $49m, or $0.32 loss

The agreement grants Jingxin Pharma exclusive rights to develop and market EVT 201 in China. Evotec is expected to receive a small upfront payment, together with commercial milestones

B Braun was recently notified by its supplier, Scientific Protein Laboratories LLC (SPL), that an additional testing of retained crude heparin samples used by SPL to manufacture this